Background: Lung cancer is the leading cause of death in the United States. We are challenged with finding the optimal treatment for patient subgroups in a real-world setting. Treatment options have expanded to include immunotherapies versus platinum-based therapies to improve the quality of cancer care. Platinum combinations are known to have overall response rates of 25%–35%, time to progression of 4–6 months, and a median survival of 8–10 months. The purpose of this study was to determine how long metastatic NSCLC patients were on first-line treatments and what characteristics potentially contribute to the duration of therapy prior to progression. Methods: All patients with a diagnosis of metastatic NSCLC that received first line treatment between January 1, 2016 and December 31, 2017 but later switched to a different treatment because of disease progression or intolerance were included in the study (n=1,222). The sample, obtained from a nationwide database of treatment requests, was stratified into 4 groups based on the type of treatment the patient received: single agent (n=66), PD-1/PDL-1 (n=157), platinum doublet (n=720), and platinum triplet (n=279). Chi-square and Kruskal-Wallis tests were performed as appropriate. Results: The findings suggested that the median duration to progression was shorter for single agents as compared to multiple agent treatments (Χ2=7.67, P=.05). The median treatment duration for the groups were as follows: 90 days for single agent, 90 days for PD-1/PDL-1, 93 days for platinum doublet, and 111 days for platinum triplet. Additional analyses were conducted to understand whether pathway adherence and growth factor usage impact the duration of time to discontinuation within each group. Conclusions: These data provide insight into the duration of first line treatments for advanced lung cancer. Shorter duration times were found for single agent treatments as compared to multiple agent treatments.